MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

37.17 1.53

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.58

Massimo

37.18

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+140.63% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-901M 3.6B
Apertura precedente	35.64
Chiusura precedente	37.17

Notizie sul Sentiment di mercato

By Acuity

50%

166 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2026, 17:11 UTC

I principali Market Mover

Principali Notizie su Eventi

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 apr 2026, 17:10 UTC

Principali Notizie su Eventi

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 apr 2026, 00:00 UTC

Principali Notizie su Eventi

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 apr 2026, 23:47 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 apr 2026, 21:01 UTC

Principali Notizie su Eventi

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 apr 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

2 apr 2026, 20:41 UTC

Utili

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 20:32 UTC

Discorsi di Mercato

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 apr 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 20:09 UTC

Discorsi di Mercato

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 apr 2026, 20:01 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:46 UTC

Discorsi di Mercato

Is Oil the New GameStop? -- Market Talk

2 apr 2026, 19:35 UTC

Discorsi di Mercato

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 apr 2026, 19:29 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:24 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 apr 2026, 19:20 UTC

Discorsi di Mercato

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 apr 2026, 19:01 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 apr 2026, 19:00 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 apr 2026, 18:24 UTC

Acquisizioni, Fusioni, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 apr 2026, 17:44 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 apr 2026, 17:32 UTC

Principali Notizie su Eventi

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 apr 2026, 17:26 UTC

Utili

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 17:17 UTC

Discorsi di Mercato

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 apr 2026, 17:09 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

140.63% in crescita

Previsioni per 12 mesi

Media 88 USD 140.63%

Alto 97 USD

Basso 67 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

166 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.